Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of USP Standards of NCGC00024983-04 on PharmaCompass.com.

    Client Email Product

    NCGC00024983-04

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    58
    US DMFs Filed

    US DMFs Filed

    38
    CEP/COS Certifications

    CEP/COS Certifications

    9
    JDMFs Filed

    JDMFs Filed

    7
    Other Certificates

    Other Certificates

    4
    Other Suppliers

    Other Suppliers

    18
    API REF. PRICE (USD / KG)
    81

    API Market Place

    18
    INTERMEDIATES
    2
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    75
    Europe

    Europe

    81
    Canada

    Canada

    17
    Australia

    Australia

    8
    South Africa

    South Africa

    32
    Uploaded Dossiers

    Uploaded Dossiers

    38
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    789.00

    Annual Reports

    690.00

    FDF Market Place

    16
    EXCIPIENTS
    253
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    18
    REF STANDARD

    EDQM

    3

    USP

    3

    JP

    0

    Other Listed Suppliers

    15
    SERVICES
    1
    left grey arrow
    right gray arrow
    Full View ScreenFull Screen View
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info

    USP

    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Nifedipine Nitrosophenylpyridine Analog (25 mg) (Dimeth...

      PDF Supplier PDF
      URL Supplier Web Content
      1463701
      N/A
      R02230
      K1F147 (31-DEC-2016)
      730
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      USP

      Contact Supplier
        Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
        Post an Enquiry Post an Enquiry
        Flag U.S.A
        Virtual Booth Virtual Booth
        Digital Content Digital Content

        Nifedipine Nitrophenylpyridine Analog (25 mg)

        PDF Supplier PDF
        URL Supplier Web Content
        1463600
        N/A
        R052Y0
        R021S0 (31-DEC-2017)
        730
        ASK
        US
        PHARMACOMPASS
        Upload
        your Marketing & Sales content

        USP

        Contact Supplier
          Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
          Post an Enquiry Post an Enquiry
          Flag U.S.A
          Virtual Booth Virtual Booth
          Digital Content Digital Content

          Nifedipine (125 mg)

          PDF Supplier PDF
          URL Supplier Web Content
          1463508
          21829-25-4
          R051Q0
          L0J059 (31-DEC-2017)
          185
          ASK
          US
          PHARMACOMPASS
          Upload
          your Marketing & Sales content
          left grey arrow
          right gray arrow
          • CAPSULE;ORAL - 10MG
          • CAPSULE;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
          • TABLET, EXTENDED RELEASE;ORAL - 30MG
          • TABLET, EXTENDED RELEASE;ORAL - 60MG
          • TABLET, EXTENDED RELEASE;ORAL - 90MG
          • TABLET, EXTENDED RELEASE;ORAL - 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
          • TABLET, EXTENDED RELEASE;ORAL - 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
          • TABLET, EXTENDED RELEASE;ORAL - 90MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
          Ask Us for Pharmaceutical Supplier and Partner
          Ask Us, Find A Supplier / Partner
          No Commissions, No Strings Attached, Get Connected for FREE

          What are you looking for?

          How can we help you?

          The request can't be empty

          Please read our Privacy Policy carefully

          You must agree to the privacy policy

          The name can't be empty
          The company can't be empty.
          The email can't be empty Please enter a valid email.
          The mobile can't be empty
          polpharma-m-2024-04-15

          Access Virtual Booth

          Contact Supplier

          View Presentation

          LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

          Access Virtual Booth

          Contact Supplier

          View Presentation

          Post Enquiry
          POST ENQUIRY

          Market Place

          Market Place

          PharmaCompass

          Home

          Market Place

          Menu

          Post Enquiry

          Post Enquiry

          Market Place

          Market Place

          Search